Lewes, DE -- (SBWIRE) -- 02/26/2016 -- Report forecast the solid tumor testing market in the US to grow at a CAGR of 11.1% during the period 2016-2020.

Solid tumor testing or screening is done for the early detection of cancer, enabling effective treatment measures to avoid the spread of cancerous cells throughout the body. The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Further, cancer testing also involves conducting genetic tests to analyze certain gene mutations that are linked to certain cancer types. Biopsy, colonoscopy, Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests that are performed for cancer screening.

The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of solid tumor testing products, such as assays or kits and bench-top instruments.

The market is divided into the following segments based on cancer types:
- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Other (including pancreatic cysts and thyroid nodules)

According to the report, Proteins and genes control various functions of the body. Any defect in a particular protein or gene structure will result in the occurrence of specific disorders. The development of personalized drugs depends on the identification and study of protein and gene expressions. These personalized medicines are regulated and labeled along with a specific diagnostic test, referred to as companion diagnostic. This tailored approach facilitates better therapeutic outcomes, owing to specific screening and selection of the patient population. This factor boosts the demand for personalized medicines, which, in turn, would drive the adoption of solid tumor testing.

Further, the report states that the regulatory and reimbursement scenario in the country has been impeding market growth ever since the government introduced medical device excise tax and cuts in bundled payments, which has restricted the use of insurance by customers.

Solid Tumor Testing Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the Solid Tumor Testing Market in the US: Abbott Molecular, Agilent Technologies (Dako), Beckman Coulter and Roche Diagnostics.

Other Prominent Vendors in the market are: 20/20 GeneSystems, Adaptive Biotechnologies, Advanced Cell Diagnostics, Affymetrix, Agena Bioscience, Ambry Genetics, ApoCell, Avant Diagnostics, Biological Dynamics, Boditech Med, Becton, Dickinson and Company (BD), Biocare Medical, Bio-Rad Laboratories, Castle Biosciences, CDx Diagnostics, Celerus Diagnostics, Cancer Genetics, Caris Life Sciences, Clarient Diagnostic Services, DiaTech Oncology, Enzo Biochem, Epic Sciences, EDP Biotech, Eutropics Pharmaceuticals, Fujirebio Diagnostics, Genalyte, Hologic, Janssen Diagnostics, Myriad Genetics, Omnyx, OxfordGene Technology, Oncospire Genomics, OncoCyte, OvaGene Oncology, Pathway Genomics, Quest Diagnostics, QIAGEN, RiboMed Biotechnologies, Sequenom, Siemens Healthcare Diagnostics, Thermo Fisher Scientific, Tosoh Bioscience and TrimGen.

Market driver
- High demand for personalized medicines
- For a full, detailed list, view our report

Market challenge
- Regulatory issues
- For a full, detailed list, view our report

Market trend
- Ready-to-use reagents
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 50 pages and 28 Exhibit "Solid Tumor Testing Market in the US 2016 - 2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market Overview, Market Landscape, Healthcare reform in US, Reimbursement and coverage: An overview, Market segmentation by technology, Market segmentation by cancer type, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://www.marketresearchreports.com/technavio/solid-tumor-testing-market-us-2016-2020

Related Report;

Cardiac Medical Devices Market in the US 2016-2020 - Visit at - http://mrr.cm/ot7

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions